MISSION & VISION

Our mission at AccuStem is to optimize outcomes for all patients with cancer across the globe.

Our mission at AccuStem is to optimize outcomes for all patients with cancer across the globe.

We take a holistic view of our role in oncology- we are here to empower patients and their care team with critical answers and tools, driving innovation in healthcare. By integrating different technologies and platforms under one umbrella, we believe we can be a stronger partner for patients, physicians, care teams and industry.

Our Team

Our Team

Wendy Blosser
Chief Executive Officer

Wendy brings 25 years of success launching, relaunching and building organizations in diagnostic, surgical and capital sales, with a focus in Oncology and Women’s Health. She has achieved record revenue growth at a variety of organizations from early-stage start ups to Fortune 500 companies. Most recently, Wendy has served as CCO at Agendia, Animated Dynamics and Biodesix. Prior to Biodesix, Wendy served as VP of Sales with Integrated Oncology (LabCorp subsidiary) where she lead the  successful integration of Genzyme Genetics following its acquisiton for $925M. Before joining Integrated Oncology, she held several leadership roles with Cytyc Corporation prior to its $6.2B acquisition by Hologic.

Jeff Fensterer
Chief Operating Officer

Jeff has spent the last 20 years with start ups at various organizational stages, leading marketing and product strategy in his most recent roles at Agendia, Animated Dynamics and Biodesix. His scientific expertise and keen commercial perspective enable organizations to take clinical data and translate it into impactful product messaging and publication strategies. His exceptional track record in long-term strategic planning is enhanced by experience in a broad spectrum of roles including marketing, sales, R&D, market access, lab operations, clinical development, business development and IT. Jeff holds a MBA from Carnegie Mellon University.

Joe Flanagan
Chief Business Officer

Joe has 25 years of sales excellence experience and is one of the most sought after talents in Oncology. He is a strategic expert, playing a leading role in the commercial development and successful launch of several product offerings from early-stage diagnostic start ups to large pharmaceutical companies. Prior to joining Accustem, Joe served as the VP of Sales for Precision Therapeutics as well as the VP of Market Development for Biodesix and Agendia. During his tenure, record revenues were realized as a result of his efforts to enhance the clinical agility and logistical focus of each company’s sales team. Most recently, he led strategic development efforts with Ambry Genetics’ Oncology franchise.

Board of Directors

Board of Directors

Gabriele
Cerrone

Wendy
Blosser

John
Brancaccio

Kunwar
Shailubhai

Willy
Simon

Our Story

AccuStem was founded in 2020 as a spinoff from Tiziana Life Sciences to commercialize a wide array of oncology products. While many organizations have focused on one of the three primary healthcare industry segments- pharmaceuticals, diagnostics or devices- our goal is to offer novel solutions across all sectors.

Our proprietary diagnostic focuses on the relationship between stem cells and cancer biology. We believe this “stemness” concept will be applicable across all tumor types. And we will bring additional value to patients and their care team by offering ancillary testing that will provide a complementary and comprehensive suite of answers for treatment planning.

Our Story

AccuStem was founded in 2020 as a spinoff from Tiziana Life Sciences to commercialize a wide array of oncology products. While many organizations have focused on one of the three primary healthcare industry segments- pharmaceuticals, diagnostics or devices- our goal is to offer novel solutions across all sectors.

Our proprietary diagnostic focuses on the relationship between stem cells and cancer biology. We believe this “stemness” concept will be applicable across all tumor types. And we will bring additional value to patients and their care team by offering ancillary testing that will provide a complementary and comprehensive suite of answers for treatment planning.

Press Releases

Find out what media is saying about AccuStem

Read Latest Release

For More Information & Updates Contact Us Today

Thank you for your message. It has been sent.

There was an error trying to send your message. Please try again later.

“Our goal at AccuStem is to build best-in-class products for the treatment and management of all cancers.

– Wendy Blosser, CEO

AccuStem CEO and CBO

“Our goal at AccuStem is to build best-in-class products for the treatment and management of all cancers”

– Wendy Blosser, CEO